MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affai MOUNTAIN VIEW, Calif., July 23 (HSMN NewsFeed) -- MAP Pharmaceuticals, Inc.(Nasdaq: MAPP ) today announced the appointment of Donald J.
Kellerman, Pharm.D.
to the position of Senior Vice President, Clinical Development and Medical...
MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affai /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc.today announced the appointment of Donald J.
Kellerman, Pharm.D.
to the position of Senior Vice President, Clinical Development and Medical Affairs.
Kellerman brings to MAP...
MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affai MOUNTAIN VIEW, Calif., July 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc.today announced the appointment of Donald J.
Kellerman, Pharm.D.
to the position of Senior Vice President, Clinical Development and Medical Affairs.
MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affai MOUNTAIN VIEW, Calif., July 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, (News) Inc.today announced the appointment of Donald J.
Kellerman, Pharm.D.
to the position of Senior Vice President, Clinical Development and Medical...
MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical Development and Medical Affai MOUNTAIN VIEW, Calif., July 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc.(Nasdaq: MAPP) today announced the appointment of Donald J.
Kellerman, Pharm.D.
to the position of Senior Vice President, Clinical Development and...
Sepracor Announces Full Support of PhRMA's Revised Code on Interactions with Healthcare Professionals -Sepracor Inc.(Nasdaq: SEPR) today announced its intention to fully support the Pharmaceutical Research and Manufacturers of America's (PhRMA) updated and enhanced Code on Interactions with Healthcare Professionals (PhRMA Code).
The...
Sepracor Announces Full Support of PhRMA's Revised Code on Sepracor Inc (SEPR) Stock Quote, Chart, News, Add to Watchlist Sepracor Inc.SEPR today announced its intention to fully support the Pharmaceutical Research and Manufacturers of Americas (PhRMA) updated and enhanced Code on Interactions...
Sepracor Announces Full Support of PhRMA's Revised Code on Interactions with Healthcare Professionals MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.(Nasdaq: SEPR) today announced its intention to fully support the Pharmaceutical Research and Manufacturers of America About Sepracor Sepracor Inc.
is a research-based pharmaceutical...
The Top 60: echo Torre Lazur Echo Torre Lazur bills itself as a small shop with a big global network behind it."What sets us apart is that we do have an intimate involvement with clients and brands, and at the same time, we have access to bigger resources," says...
The end is near for CFC-propelled inhalers With the deadline for the transition to HFA-propelled inhalers less than six months away, millions of patients still rely on the older devices.Washington -- The clock is running down for albuterol metered-dose inhalers that rely on the...
Sepracor Inc. Presented Leadership Award for Contributions to Growth of Community Company Website: http://www.sepracor.com MARLBOROUGH, Mass.-- (Business Wire) Sepracor Inc.
(Nasdaq: SEPR) today announced that it has been presented with the Ambassador Richard J.
Egan Private Sector Leadership Award by the 495...
Sepracor Inc. Presented Leadership Award for Contributions to Growth of Community MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc.(Nasdaq: SEPR - News) today announced that it has been presented with the Ambassador Richard J.
Egan Private Sector Leadership Award by the 495/MetroWest Corridor Partnership.
Awarded...
Sepracor Inc has achieved profitability following the launches of Xopenex HFA and Lunesta in 2005 General/Sepracor-Inc-PharmaV ..Introduction This analysis examines the historical and forecast performance for Sepracor in the ethical pharmaceutical sector.
The profile encompasses global company strategy, portfolio and pipeline...
Medicare contractors suspend Sepracor pricing cuts WASHINGTON (Reuters) - Medicare contractors are suspending a planned pay cut for Sepracor Inc's asthma drug Xopenex, which will also benefit oxygen suppliers Apria Healthcare Group Inc and Lincare Holdings Inc.Contractors that...
FDA: Time for asthma patients to get new inhalers Patients use inhalers that dispense airway-relaxing albuterol during asthma attacks.Chemicals called chlorofluorocarbons, or CFCs, once were widely used to propel the drug into the lungs.
But CFC-containing consumer products are being...
Sepracor inks patent settlement, license agreement with Breath Sepracor Inc.has entered into a settlement and license agreement with Breath Limited (Breath), an Arrow Group subsidiary, to resolve the patent litigation involving Sepracor's Xopenex brand levalbuterol HCl inhalation solution...
Sepracor shares fall as revenue disappoints Wall Street NEW YORK (AP) - Shares of drug developer Sepracor Inc.fell Friday as Wall Street expressed disappointment over lagging sales of the company's insomnia treatment Lunesta and the decline in first-quarter revenue.
The stock fell $1.56, or...
Sepracor downgraded to underperform at Friedman Billings Ramsey BOSTON (Thomson Financial) - Shares of Sepracor Inc.tumbled for the second consecutive session Friday after the Marlborough, Mass.-based drug manufacturer was downgraded to underperform from market perform at Friedman Billings Ramsey &...
Sepracor Inc. Reports First Quarter 2008 Results, Certain Strategic Initiatives and Settlement of XOPENEX Pate total revenues were approximately $320.8 million compared to revenues of $327.7 million during the same quarter in 2007.Excluding a $39.8 million, or $0.34 per diluted share, after-tax in-process research and development charge made...
